Effects of Oxaliplatin-Induced Peripheral Neuropathy on Hand Function, Grip Strength and Quality of Life in Colorectal Cancer Patients

NCT07203066 | Completed

• 1 other identifier: TY-2025-2260
• Study Type: observational
• Target: 103
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to investigate the effects of oxaliplatin-induced peripheral neuropathy on hand function, grip strength, and quality of life in colorectal cancer patients. Assessing the motor symptoms of CIPN and sharing the results in clinical settings will help guide evidence-based practices and interventions.

Conditions

Peripheral Neuropathy Due to Chemotherapy; Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients; Hand Strength

Keywords

Colorectal Cancer; Oxaliplatin; Chemotherapy-Induced Peripheral Neuropathy; Hand Function

Outcome Measures

Primary Outcomes (6)

• Hand Grip Strength Assessment

  Participants' hand grip strength will be evaluated using the Saehan Hydraulic Hand Dynamometer (SAEHAN Corporation, Yangdeok-Dong, Masan, South Korea) to assess the functional status of the upper extremity and clinical outcomes.

  baseline only

• Finger Grip Strengths (Tip, Key, and Palmar Grip)

  A hydraulic pinch gauge will be used to measure finger grip strengths.

  baseline only

• Hand Function Assessment (Duruöz Hand Index)

  Hand function related to daily activities will be assessed using the Duruöz Hand Index questionnaire. This questionnaire consists of 18 items covering five domains: kitchen tasks, dressing, personal hygiene, work activities, and other activities. Each item is scored on a scale from 0 to 5.

  baseline

• Hand Function Assessment (Michigan Hand Outcomes Questionnaire)

  Overall hand function, including parameters such as pain, aesthetic perception, and patient satisfaction, will be assessed using the Michigan Hand Outcomes Questionnaire (MHQ). The MHQ was developed in 1998 by hand surgeon Chung and colleagues Pillsbury, Walters, Hayward, and Arbor. The questionnaire consists of six domains: overall hand function, activities of daily living, work performance, pain, aesthetics, and patient-reported hand function. Scores range from 0 to 100. Responses are rated on a scale of 1 to 5 and then normalized to obtain scores for each subdomain.

  baseline

• Fine Motor Skill Assessment (Minnesota Manual Dexterity Test)

  Fine motor skills will be assessed using the Minnesota Manual Dexterity Test (MMDT), which evaluates unilateral and bilateral manual performance of the upper extremities through placement and turning tasks. In the placement test, participants are required to place 60 cylinders one by one into holes on a board as quickly as possible using one hand. The dominant and non-dominant hands are evaluated separately. In the turning test, at the start of the test, all 60 cylinders are placed in the holes. Participants are asked to pick up each cylinder with one hand, rotate it, and return it to the hole using the other hand, repeating this process for all 60 cylinders individually.

  baseline

• Nine-Hole Peg Test (NHPT)

  The Nine-Hole Peg Test is a standardized, well-established, and reliable tool for assessing hand function.

  Baseline

Secondary Outcomes (2)

• European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

  baseline

• European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy Module (EORTC QLQ-CIPN20)

  baseline

Interventions

observational only OTHER

observational only

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

colorectal cancer patients who received oxaliplatin based chemotherapy

You may qualify if:

• Receiving chemotherapy due to a diagnosis of locally advanced or metastatic colorectal cancer,
• Having received at least 3 cycles of single or combined oxaliplatin-based chemotherapy,
• Aged 20 years or older,
• No speech or hearing impairments,
• Voluntary participation in the study.

You may not qualify if:

• Development of peripheral neuropathy due to causes other than chemotherapy (e.g., tumor compression, nutritional disorders, infections, or major systemic diseases such as diabetes mellitus),
• Presence of mental or cooperation problems.

Sponsors & Collaborators

• Fenerbahce University: lead
• Acibadem University: collaborator

Study Sites (1)

Cemil Tascioglu City Hospital

Istanbul, Turkey (Türkiye)

Location

Related Publications (2)

• Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007 Dec;20(6):719-25. doi: 10.1097/WCO.0b013e3282f1a06e.

  PMID: 17992096 RESULT

• Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer research for cancer prevention. Lyon (FR): International Agency for Research on Cancer; 2020. Available from http://www.ncbi.nlm.nih.gov/books/NBK606505/

  PMID: 39432694 RESULT

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: research assisstant

Study Record Dates

• First Submitted: September 24, 2025
• First Posted: October 2, 2025
• Study Start: April 24, 2025
• Primary Completion: January 20, 2026
• Study Completion: January 27, 2026
• Last Updated: June 1, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)